The successful development and performance of direct-acting antiviral agents (DAAs) for the cure of hepatitis C virus (HCV) infection is changing the utilization of HCV+ kidneys for transplantation.
| INTRODUC TI ON
The successful development and performance of direct-acting antiviral agents (DAAs) for the cure of hepatitis C virus (HCV) infection is changing the utilization of HCV+ kidneys for transplantation.
Early after the development of serologic tests for HCV, some recommended that serologic-positive organs not be used. 1 Given the organ shortage and lack of therapy, others advocated transplanting kidneys from HCV donor positive (D+) only into recipients infected with HCV (R+). 2, 3 This was not acceptable to all centers, in part because of concerns of superinfection with different genotypes. 4, 5 Many centers have remained averse to using HCV+ organs, and there remains a high discard rate in some regions. 6 HCV+ patients with chronic kidney disease, including kidney transplant recipients have now been treated successfully with DAAs, with cure rates equivalent to the general population at >95%. 7 With respect to allocation, a recent draft international guideline states that DAA treatment of waitlisted infected candidates can be deferred, if delaying therapy improves the chance of transplantation. 8 The proponents of using HCV D+ organs argue that the recipients benefit more by earlier transplantation, often with an otherwise ideal organ, rather than remaining on the waitlist at increased risk of death. 6 Although transplantation may be earlier in those willing to receive a D+ organ, the overall wait time might be more than several years in many. Based on the percentage of R+ recipients transplanted each was preferred for regions with much greater access to HCV+ organs or in patients with very low HCV+-associated mortality. The best option from an individual patient's perspective will differ by region and candidate.
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clinical decision-making, health services and outcomes research, infection and infectious agents -viral: hepatitis C, infectious disease, kidney transplantation/nephrology, mathematical model, quality of life (QOL) year, about 5-6% of all (100 000 in 2015) waitlist candidates are infected. 9, 10 Only about 35% of transplant HCV+ recipients receive an HCV+ kidney organ. 9 If most D+ kidneys retrieved were transplanted, there could be about 500-700 HCV+ organs annually. 6, 9, 10 Because this estimation is based on data where only serology is recorded, the numbers of viremic (serology positive and nucleic acid testing [NAT] positive) donor kidneys will be less. 10 A recent study found that 30%
of HCV serology-positive organ donors were not viremic by NAT testing. 11 Although some HCV-infected patients active on the list will be transplanted within 2 years, many would be left untransplanted and be exposed to the higher morbidity and mortality associated with HCV.
The increased risk associated with HCV varies from study to study.
The hazard ratio for death ranges from 1.12 to 1.79 in various endstage renal disease (ESRD) populations. 6, [12] [13] [14] [15] [16] [17] [18] [19] Delays in treatment may adversely affect those that are not promptly transplanted from HCV related death, greater risk of withdrawal from the list, or being put on hold for HCV related medical problems.
Depending on regional supply and demand for HCV+ organs (prevalence of HCV+ patients on the list) and other factors such as degree of sensitization, some HCV+ recipients may have longer wait times. Treatment may not benefit all to the same degree and some with more advanced hepatic disease may continue to be at increased risk of HCV-related mortality and morbidity. 20 Delaying therapy for an unknown and potentially long period of time may not be in the patient's best interest. HCV infection is a systemic disease that increases the risk of cancer and diabetes mellitus, and contributes to progressive kidney failure. 21, 22 Although there is no direct evidence from randomized controlled trials that DAA improves survival in patients with ESRD, the absence of evidence does not necessarily mean the lack of benefit. There are also indirect benefits for prompt therapy. Treatment could theoretically reduce the potential for community and nosocomial spread.
A formal decision analysis would be ideal. Regional supply of D+ organs, year-to-year variation in supply, effectiveness of therapy in waitlisted HCV+-potential recipients to reduce mortality and morbidity, DAA treatment availability, and the small risk of treatment failure make the best option difficult to predict with certainty. The purpose of this medical decision analysis is to determine who is best treated early and who can delay HCV treatment in order to potentially be transplanted earlier.
| ME THODS
A Markov model was created to examine outcomes in a cohort of US patients who had HCV infection and were listed for a kidney transplant alone. In the model, patients initially are on the wait list and can transition over time to being transplanted, die on the list, or be withdrawn for medical reasons. Those withdrawn remain on dialysis until death. Those transplanted can transition to death with a functioning transplant or return to dialysis (see Figure 1 ). Given that this is a theoretical model that uses published population data, ethics approval was not required. Renal Data System (USRDS) data report. 23 Rates were converted to annual probabilities for each 5-year age interval.
2.
Patients have access to DAA therapy both before and after kidney transplantation and will be cured of the infection. Patients without coverage were not considered in this analysis. For Option 2, patients with treatment failure were excluded from the analysis as they would similarly have treatment failure after transplantation.
It is possible that HCV+ organs transplanted could come from a donor with unknown or unreported prior treatment failure and drug resistant virus, but this was not modeled (favors Option 1).
3.
Patients were on the deceased donation wait list, without the option for a live donor kidney. Treatment reduces the excess risk by 65%. 20 We assumed that therapy was unable to completely eliminate the increased risk compared to a noninfected waitlisted patient.
6.
The relative risks of death and withdrawal from the wait list were assumed to be proportionally the same over time. The baseline increased risk of death (and withdrawal) was 1.29 in untreated HCV+ patients compared to noninfected patients. 6, [12] [13] [14] [15] [16] [17] [18] [19] Withdrawal from the list was 50% of the mortality rate on the waitlist. The cycle length was yearly, and the time horizon was 50 years, at a time that most grafts and patients would have died.
| Sensitivity analyses
1. Given regional differences, higher and lower overall cumulative transplant incidence rates and availability of HCV+ organs were explored. The registry shows that the cumulative incidence of transplantation for those listed within 5 years varies from a lowest of 7.8% to a highest of 82.7% across regions in the United States (20th percentile 25.8% and 80th percentile 58.5%). 9 In the sensitivity analysis, the 5-year cumulative incidence of deceased HCV-kidney transplantation was modeled to range from a "low" of 16% to a "high" of 70%. The percentage of HCV+ organs transplanted to HCV+ recipients varies from 0% to nearly 100% among centers. 6 In the model's sensitivity analysis, the 5-year cumulative incidence of transplantation with an HCV+ organ was varied from a "low" of 1% to a "high" of 20%. However, if the availability of HCVorgans was "low" and the availability of HCV+ organs was 2. Given the uncertainty of the increase in risk of death and withdrawal off the waitlist associated with HCV, a range of relative mortality risk values were examined (Table 1) . [12] [13] [14] [15] [16] [17] [18] [19] 3. Variation in the impact on treatment (efficacy) to reduce mortality risk was examined (Table 1) . Since a systematic review found that efficacy to reduce death varied with severity of HCV associated disease, a range of efficacies (50 to 80% risk reduction) were examined. 
4.
Because transplantation is associated with better quality of life, utility scores for the health states to calculate quality adjusted life years (QALYs) were also included in the analysis. The model assumed that the ideal reference state, transplantation, had a utility value of 1. The waitlist health state was assumed to be the same as dialysis (see Table 1 ), and both were modeled to be less than transplantation. The model also assumed that active HCV infection would be associated with some reduction in quality of life in waitlisted and dialysis patients and that this would improve with a sustained viral response. 25, 26 Because there are no relevant published health utility studies on HCV-infected waitlisted patients before and after transplantation, a range of values was TA B L E 1 Selected variables in model examined. Although a reduced quality of life while being administered antiviral therapy has been modeled in the past, 27 this was not included in the analysis, since the treatment course is relatively short and a considerable number of subjects in Option 1 will also receive treatment (favors Option 2). QALYs were discounted at 3%. 23 TreeAge PRO Healthcare 2015 (TreeAge Software Inc., Williamstown, MA) was used for this medical decision analysis.
5.
One-way analyses were performed for the key variables of interest.
Monte Carlo microsimulation was used to determine 95% confidence intervals (CIs) for the main outcome variables (Table 1) . Uncertainty in the relative risk of mortality associated with HCV infection and the efficacy of treatment was examined using a probabilistic sensitivity analysis. In the simulation, 100 parallel head-to-head trials of 100 patients were run. Differences in outcomes in the parallel trials were used to calculate mean differences between options with 95% CIs.
| RE SULTS
Option 1 patients were transplanted 1 year earlier with a higher cumulative incidence of 54% at 5 years posttransplantation (compared to 45% for Option 2). Figure 2A shows Cumulative Incidence of Transplantation with HCV resulted in net benefit for Option 1. Very high rates of HCV+ organ availability were also associated with a survival advantage for Option 1 (see Figure 2B for cumulative incidence of transplantation between options that favored Option 1). Figure 4 shows a 2-way sensitivity analysis where availability of HCV+ organs and associated risk of death with HCV infection were varied simultaneously. Figure 5 shows the tornado plot for the key variables on the incremental QALYs projected for Option 1 compared to Option 2.
Under most circumstances, Option 2 was preferred. However, high availability of HCV+ organs and low relative risks of mortality associated with HCV infection favored Option 1 (Delay Therapy).
| D ISCUSS I ON
The study shows that delaying therapy for HCV infected waitlist patients may not be in their best interest despite the promise of earlier transplantation. As shown, earlier transplantation does not always overcome the deleterious effects of untreated HCV infection while on the waitlist. There are several caveats to this analysis.
The increased mortality risk associated with HCV infection and the availability of HCV+ organs that are preferentially directed to HCV+ recipients are key variables that change this net benefit. The study also supports delaying DAA therapy to expedite transplantation to HCV+ waitlist recipients; however, a center must have access to a ready supply of HCV+ organs, and the individual's burden of HCV disease should be considered in the decision to defer treatment.
Despite fluctuations from month to month, there is likely good information on organ availability in donor service areas regarding cumulative procurement rates and HCV+ organ availability. What is less well known is assigning a relative mortality risk associated with HCV infection in an individual and taking into account rate of liver disease progression. There is a considerable variation in the literature. [12] [13] [14] [15] [16] [17] [18] [19] The baseline value chosen was the median relative risk of the 8 studies reviewed, and these included both dialysis and transplant recipients. Several studies find the adjusted relative risks to be much higher (>1.5), with the exception of a recent large international hemodialysis cohort analysis that found a hazard ratio of only 1.12. 12 In a study of HCV+ subjects who attempted to donate blood and who were felt to be healthy, HCV+ status was associated with higher relative risks (3.1 fold) of death. 28 Therefore, a baseline risk Unfortunately DAA therapy is not always available to patients.
We assumed in the model that therapy was available. Earlier transplantation is the better option for those who do not have access to therapy. We did not present a detailed cost-effective or cost-utility analysis. Using dialysis and transplant (year 1 and >year 1) costs from 2015 United States Renal Data System, and assuming one-time DAA treatment costs of $84 000, the incremental costs/QALY (constant $2013, discount rate 3%) would be about $406 000/QALY in this analysis. 29, 30 However, assuming much lower quality of life in untreated HCV-infected waitlisted patients (utility 0.6) compared to uninfected waitlisted patients (utility 0.8), the incremental costs/ QALY would drop to $155 400/QALY.
Of interest, the treat-first approach (Option 2) is consistent with recommendations in patients with significant HCV+-associated liver disease. Early treatment is projected to improve outcomes in many patients awaiting liver transplant rather than deferring therapy. 31, 32 However, in the analysis of liver disease, receiving an HCV viremic organ earlier. 33 Although not modeled specifically, kidney disease patients with significant residual func-
tion not yet on dialysis should have reduced rates of progression to ESRD with DAA treatment and may potentially benefit more from early intervention. 34 One area of concern is that with the increased retrieval of HCV+ organs over the last several years that the median time to transplantation may be better than 1 year earlier in some centers preferentially allocating D+ kidneys to R+ recipients. We assumed the baseline of 1 year earlier from the available literature. 10 From the 2010 annual report, 6.6% of the deceased donor kidney transplant recipients were HCV+ and 1.9% (29%) of these received a HCV+ organ. 35 According to the most recent report, 6.6% of the deceased donor kidney transplant recipients were HCV+ and 2.5% (38%) of these received a HCV+ organ. 36 Although there are slightly more HCV D+R+ kidney transplants in current US transplant cohorts, most HCV+ recipients are still receiving HCV-kidney organs. Unfortunately we do not know what the current median times are across service areas for HCV+ recipients. In the base case analysis, we assumed that 38%
of HCV+ recipients with delayed therapy (Option 1) would receive an HCV+ kidney. In the sensitivity analysis, we examined situations where 75% of the HCV+ recipients were transplanted with an HCV+ organ. This was associated with a median time to transplantation of 2.5 years earlier (see Figure 2B , which is equivalent to high availability seen in Figures 3 and 4) for the delayed option. Under these circumstances delayed therapy was superior.
There are limitations to this study. Some of the assumptions favored delay in treatment such as not modeling the need for combined kidney liver transplantation, not including potential carryover effects of longer exposure to HCV (higher rates of cancer, cardiovascular disease, infection, and diabetes mellitus), or obtaining a virus from the HCV+ organ that is resistant to therapy. Including these probabilities would not change the conclusions of the analysis. Conversely we did not model the disutility of DAA therapy.
However, the duration of treatment is short, and significant numbers in the delayed arm would also be treated. There are no studies on the impact of treatment to reduce the excess risk associated with HCV in waitlist or transplant recipients; however, this uncertainty was necessary. There will be added costs and logistic time, but these costs will be small relative to the cost savings and overall benefit afforded by transplantation over dialysis. 29, 37 Where this analysis challenges the delayed treatment policy is in areas of relatively low supply and high demand, where many HCV+ recipients may wait too long without HCV therapy and will either die or be withdrawn from the list due to an HCV-associated illness, and if transplanted are more likely to have received an HCV-organ. Minimizing the adverse effects of HCV infection is also an important goal. In addition, there is likely a point in some regions and some countries, now or in the future, where the supply of HCV+ organs will be greater than the demand, as more and more patients will have 
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